Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Cuppone, Federica ^a   Bria, Emilio ^a   Giannarelli, Diana ^a   Vaccaro, Vanja ^a   Milella, Michele ^a   Nisticò, Cecilia ^a   Ruggeri, Enzo M ^b   Sperduti, Isabella ^a   Bracarda, Sergio ^d   Pinnarò, Paola ^a   Lanzetta, Gaetano ^c   Muti, Paola ^a   Cognetti, Francesco ^a   Carlini, Paolo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b BELCOLLE HOSPITAL   (Italy)

^c Istituto Neurotraumatologico Italiano   (Italy)

^d IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVANCED CANCER; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; GLEASON SCORE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; OVERALL SURVIVAL; PREDICTION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; MALE; MORTALITY; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TIME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649775821     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-675     Document Type: Article

References (46)

1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. Jama 2005, 294:238-244. 10.1001/jama.294.2.238, 16014598.
2. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-106. 10.1016/S0140-6736(02)09408-4, 12126818.
3. Bolla M, van Tienhoven G, de Reijke TM, van den Bergh AC, van der Meijden AP, Poortmans PM, Gez E, Kil P, Pierart M, Collette L, Groups E. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961. J Clin Oncol (Meeting Abstracts) 2007, 25:5014-.
4. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. Jama 2008, 299:289-295.
5. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. Jama 2004, 292:821-827.
6. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005, 6:841-850. 10.1016/S1470-2045(05)70348-X, 16257791.
7. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 2004, 171:1137-1140. 10.1097/01.ju.0000112979.97941.7f, 14767287.
8. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50:1243-1252. 10.1016/S0360-3016(01)01579-6, 11483335.
9. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290. 10.1016/j.ijrobp.2004.08.047, 15817329.
10. Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26:585-591. 10.1200/JCO.2007.13.9881, 18172188.
11. See WA, Tyrrell CJ. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol 2006, 132(Suppl 1):S7-16. 10.1007/s00432-006-0132-6, 16896884.
12. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnaro P, Terzoli E, Cognetti F, Carlini P. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer 2009, 115:3446-3456. 10.1002/cncr.24392, 19484790.
13. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Lawton C, Shipley W, Cox J. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000, 47:617-627. 10.1016/S0360-3016(00)00577-0, 10837944.
14. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006, 24:3979-3983. 10.1200/JCO.2006.05.9741, 16921050.
15. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164. 10.1056/NEJMoa041943, 15647578.
16. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8:162-200.
17. Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 8:145.
18. Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ, Laplante S. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 1996, 156:873-877. 10.1016/S0022-5347(01)65645-3, 8709351.
19. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995, 154:424-428. 10.1016/S0022-5347(01)67067-8, 7541859.
20. Pignon JP, Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2001, 2:475-482. 10.1016/S1470-2045(01)00453-3, 11905723.
21. Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nistico C, Terzoli E, Cognetti F, Giannarelli D. Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?: a meta-analysis of 20 phase 3 trials. Cancer 2007, 110:525-533. 10.1002/cncr.22809, 17577216.
22. Higgins JPT, Green S. Cochrane handbook for Systematic Reviews of intervention 4.2.6 [updated sep 2006]. The Cochrane Library 2006, (4). Chichester, UK: John Wiley & Sons, Ltd.
23. Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist 2002, 7:181-187. 10.1634/theoncologist.7-3-181, 12065789.
24. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis 2009, Chichester, West Sussex, UK: John Wiley & Sons, Ltd. Publication.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
26. Shuster JJ. Empirical vs natural weighting in random effects meta-analysis. Stat Med 29:1259-1265. 10.1002/sim.3607, 19475538.
27. Cochran WG. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
28. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002, 21:1575-1600. 10.1002/sim.1188, 12111921.
29. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index?. Psychol Methods 2006, 11:193-206. 10.1037/1082-989X.11.2.193, 16784338.
30. Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti I, Carlini P, Terzoli E, Cognetti F, Giannarelli D. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer 2009, 63:50-57. 10.1016/j.lungcan.2008.05.002, 18565615.
31. Parmar MKB, Machin D. Survival analysis: a practical approach 1995, Chichester (England): John Wiley.
32. Altman DG. Confidence intervals for the number needed to treat. Bmj 1998, 317:1309-1312. 1114210, 9804726.
33. Bolla M, Collette L, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff ROM, Storme G, Bernier J, Kuten A, Piérart M. Ten Year Results of Long Term Adjuvant Androgen Deprivation with Goserelin in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy: A Phase III EORTC Study. International Journal of Radiation Oncology & Biology & Physics, American Society for Therapeutic Radiology and Oncology (ASTRO) 50th Annual Meeting September 1st, 2008; Boston 2008, S30-S31. Elsevier.
34. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527. 10.1056/NEJMoa0810095, 19516032.
35. Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 60:15-23. 10.1016/j.ijrobp.2004.02.022, 15337535.
36. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504. 10.1200/JCO.2007.14.9021, 18413638.
37. Armstrong JG, Gillham CM, Dunne MT, Fitzpatrick DA, Finn MA, Cannon ME, Taylor JC, O'Shea CM, Buckney SJ, Thirion PG. A Randomized Trial (Irish Clinical Oncology Research Group 97-01) Comparing Short Versus Protracted Neoadjuvant Hormonal Therapy Before Radiotherapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys
38. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnaro P, Terzoli E, Cognetti F, Carlini P. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-Analysis of Randomized Trials. Cancer 2009,
39. Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:327-333. 10.1016/j.ijrobp.2008.04.075, 18707821.
40. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009, 302:866-873. 10.1001/jama.2009.1137, 19706860.
41. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487. 10.1016/S1470-2045(07)70143-2, 17482880.
42. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74. 10.1016/j.ijrobp.2007.06.054, 17765406.
43. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105. 10.1016/S0360-3016(02)02829-8, 12128107.
44. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233-1239. 10.1001/jama.294.10.1233, 16160131.
45. Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 2009, 27:2137-2143. 10.1200/JCO.2008.17.4052, 2674000, 19307511.
46. Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P, Pai H, Ludgate C. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3-versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 76:23-30.